10 Firms Kick Off Shortened Trading Week With Impressive Gains

8. Moderna, Inc. (NASDAQ:MRNA)

Shares of Moderna, Inc. (NASDAQ:MRNA) ended firmer for a third day, adding 8.37 percent to end Tuesday’s trading at $35.75, as investors took path from the company’s long-term outlook, shunning dismal earnings performance last year.

In its earnings release on Friday, MRNA said it would focus on driving sales this year and deliver up to 10 product approvals until 2027.

“By the end of 2025, we aim to remove nearly $1 billion in costs. With strong momentum in our late-stage pipeline, we anticipate multiple approvals starting this year, along with key Phase 3 readouts that will support our long-term growth,” said MRNA CEO Stephane Bancel.

In the fourth quarter of 2024, MRNA swung to a net loss of $1.12 billion versus a net income of $217 million in the same period a year earlier. However, net losses narrowed by 24 percent for the full year, ending at $3.561 billion versus $4.7 billion in 2023.

Revenues for the quarter also fell by 66 percent to $966 million from $2.811 billion year-on-year, while revenues for the full year plummeted by $3.236 billion from $6.848 billion in the same comparable period.